Figure 5.

Cilengitide enhances the in vivo antitumor effect of anti-PD1 antibody in B16 murine melanoma model. (A, B, and D) Tumor volumes of C57BL/6 mice in different treatment groups (n = 6). (c) Quantified results of tumor weights at day 21 (n = 6). (e) Survival time of mice in different treatment groups (n = 6). (f) Quantified results of mice’s body weight (n = 6). (g) Tumors were detected by bioluminescence assay at 8 and 20 days after tumor implantation (n = 2). Data were represented as mean ± standard deviation. *p < 0.05, **p < 0.01, ***p < 0.001, NS, not significance (Student’s t test) and *p < 0.0332, **p < 0.0021, ***p < 0.0002, NS, not significance (Kaplan-Meier survival analysis). The in vivo experiments were repeated three times.